← Back to Clinical Trials
Recruiting NCT05332457

NCT05332457 The Effect of Beta-blocker on Chronotropic Response and Cardiorespiratory Fitness in Patients With Atrial Fibrillation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05332457
Status Recruiting
Phase
Sponsor National Taiwan University Hospital
Condition Atrial Fibrillation
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-07-01
Primary Completion 2025-07-31

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Reduced dosage of beta-blocker

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-07-01 with a primary completion date of 2025-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective study to evaluate changes in exercise capacity and chronotropic response to exercise before and after beta-blocker dosage reduction in patients with atrial fibrillation (AF).

Eligibility Criteria

Inclusion Criteria: 1. \> 20 years of age. 2. Clinically stable patients with persistent atrial fibrillation using beta-blocker as rate-control agent without dosage adjustment for at least 3 months. 3. Resting heart rate \< 80 bpm. 4. Left ventricular ejection fraction \> 50%. Exclusion Criteria: 1. Beta-blocker usage due to indications other than rate control for atrial fibrillation. 2. Inability to perform a cardiopulmonary exercise testing. 3. Presence of contraindications for cardiopulmonary exercise testing according to the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription. 4. Patients with implantable cardioverter defibrillator or pacemaker. 5. Pregnancy. 6. Inability to provide informed consent.

Contact & Investigator

Central Contact

Hung-Jui Chuang, MD

✉ 103311@ntuh.gov.tw

📞 00886-2-23123456

Principal Investigator

Hung-Jui Chuang, MD

PRINCIPAL INVESTIGATOR

Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital

Frequently Asked Questions

Who can join the NCT05332457 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05332457 currently recruiting?

Yes, NCT05332457 is actively recruiting participants. Contact the research team at 103311@ntuh.gov.tw for enrollment information.

Where is the NCT05332457 trial being conducted?

This trial is being conducted at Taipei, Taiwan.

Who is sponsoring the NCT05332457 clinical trial?

NCT05332457 is sponsored by National Taiwan University Hospital. The principal investigator is Hung-Jui Chuang, MD at Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital. The trial plans to enroll 40 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology